281 related articles for article (PubMed ID: 34759146)
1. Continued-Maintenance Therapy with High-dose Methotrexate Improves Overall Survival of Patients with Primary Central Nervous System Lymphoma.
Nakajima K; Mizobuchi Y; Fujihara T; Azumi M; Takagi Y
J Med Invest; 2021; 68(3.4):286-291. PubMed ID: 34759146
[TBL] [Abstract][Full Text] [Related]
2. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
Yu J; Du H; Ye X; Zhang L; Xiao H
Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
[TBL] [Abstract][Full Text] [Related]
3. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
4. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
[TBL] [Abstract][Full Text] [Related]
5. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
7. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
[TBL] [Abstract][Full Text] [Related]
9. [Clinical Efficacy of High Dose Methotrexate, Temozolomide and Rituximab in the Treatment of Patients with Primary Central Nervous System Lymphoma].
Pang DW; Chen FL; Guo HG; Jiang XM; Wei XJ; Liu SC; Huang L; Liang ZL; Li WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1175-1180. PubMed ID: 34362499
[TBL] [Abstract][Full Text] [Related]
10. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
J Neurooncol; 2021 Sep; 154(2):207-217. PubMed ID: 34331673
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
DeAtkine AB; Abdelrashid M; Tucker Z; Mehta A; Markert JM; Kim J; Fiveash JB; Oster RA; Lobbous M; Nabors LB
J Neurooncol; 2022 May; 158(1):33-40. PubMed ID: 35441948
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study.
Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Tantiworawit A; Norasetthada L
Int J Clin Oncol; 2021 Oct; 26(10):1805-1811. PubMed ID: 34236556
[TBL] [Abstract][Full Text] [Related]
13. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
[TBL] [Abstract][Full Text] [Related]
14. A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.
Li Q; Ma Y; Lin Z; Ma J; Kang H; Zhang M; Xu H; Chen B
J Neurooncol; 2023 May; 163(1):39-46. PubMed ID: 35733032
[TBL] [Abstract][Full Text] [Related]
15. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
Holdhoff M; Ambady P; Abdelaziz A; Sarai G; Bonekamp D; Blakeley J; Grossman SA; Ye X
Neurology; 2014 Jul; 83(3):235-9. PubMed ID: 24928128
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
[TBL] [Abstract][Full Text] [Related]
17. Advances and challenges in the treatment of primary central nervous system lymphoma.
Yang H; Xun Y; Yang A; Liu F; You H
J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
[TBL] [Abstract][Full Text] [Related]
18. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma.
Kobayashi H; Yamaguchi S; Motegi H; Kaneko S; Endou S; Onimaru R; Terasaka S; Houkin K
J Chemother; 2019 Feb; 31(1):35-41. PubMed ID: 30773132
[TBL] [Abstract][Full Text] [Related]
20. Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).
Miyakita Y; Ohno M; Takahashi M; Muragaki Y; Katai H; Narita Y
Jpn J Clin Oncol; 2017 Oct; 47(10):919-924. PubMed ID: 28981729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]